Dergiler / Cyprus Journal of Medical Sciences / 2021 / Cilt: 6 - Sayı: 3

Imaging Features of Nonenhancing Diffuse Midline Gliomas (DMGs) with Histone H3 K27M Mutation: Spectroscopy and Perfusion Imaging Findings

Sayfa
265–267
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

In conclusion, perfusion and spectroscopy findings are helpful for nonenhancing DMG diagnosis.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Diffuse midline gliomas (DMGs) with the histone H3 K27 mutation is a brand-new tumor according to the 2016 World Health Organization Classification of Tumors of the Central Nervous System.
📊
Temel Bulgular & Veri:We present the case of high-grade astrocytic tumors with H3 K27 mutation in a 19- year-old woman.
💡
Sonuç & Katkı:In conclusion, perfusion and spectroscopy findings are helpful for nonenhancing DMG diagnosis.
🔬Tür:Literatür & Derleme Çalışması
📍Kapsam:2016 Verileri
⚙️Değişkenler:Alan Parametreleri

Özet

Diffuse midline gliomas (DMGs) with the histone H3 K27 mutation is a brand-new tumor according to the 2016 World Health Organization Classification of Tumors of the Central Nervous System. In this case report, we characterize the magnetic resonance imaging (MRI) aspects with the literature review. Instead of biopsy, MRI techniques are used to diagnose the tumor and determine the treatment choice despite the correlation with the prognosis. We present the case of high-grade astrocytic tumors with H3 K27 mutation in a 19- year-old woman. MRI revealed a DMG. There was no paralysis of extremities or cerebellar deficit detected in physical examination. MRI showed a tumor in the pons, which is a hypo intense on T1-weighted imaging and a hyper intense on T2-weighted imaging. A nonenhancing lesion was discovered during a Gd-MRI examination. In perfusion imaging, there was no distinct perfusion rising in the tumor. N-Acetyl-aspartate (NAA):Cr ratio was 0.57, and choline (Cho):Cr ratio was 0.78. In conclusion, perfusion and spectroscopy findings are helpful for nonenhancing DMG diagnosis.

🔖

Bu Makaleye Atıf Yap

TUNÇYÜREK, Ö., DİRİK, M., BULAKBAŞI, N. (2021). Imaging Features of Nonenhancing Diffuse Midline Gliomas (DMGs) with Histone H3 K27M Mutation: Spectroscopy and Perfusion Imaging Findings. Cyprus Journal of Medical Sciences, Cilt: 6 - Sayı: 3, 265–267. https://ajindex.com/articles/413620

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (13)

  1. Johnson DR, Guerin JB, Giannini C, Morris JM, Eckel LJ, Kaufmann TJ. Updates to the WHO brain tumor classification system: What the radiologist needs to know. Radiographics. 2017
  2. 37(7):2164-2180. [CrossRef] 2. Castel D, Philippe C, Kergrohen T, et al. Transcriptomic and epigenetic profiling of ‘diffuse midline gliomas, H3 K27M-mutant’ discriminate two subgroups based on the type of histone H3 mutated and not supratentorial or infratentorial location. Acta Neuropathol Commun. 2018
  3. 6(1):117. [CrossRef] 3. Nakata S, Nobusawa S, Yamazaki T, et al. Histone H3 K27M mutations in adult cerebellar high-grade gliomas. Brain Tumor Pathol. 2017
  4. 34(3):113-119. [CrossRef] 4. Buczkowicz P, Hawkins C. Pathology, molecular genetics, and epigenetics of diffuse intrinsic pontine glioma. Front Oncol. 2015
  5. [CrossRef] 5. Smith M, Freidlin B, Ries LA, Simon R. Trends in reported incidence of primary malignant brain tumors in children in the United States. J Natl Cancer Inst. 1998
  6. [CrossRef] 6. Hankinson TC, Campagna EJ, Forman NK, Handler MH. Interpretation of magnetic resonance images in diffuse intrinsic pontine glioma: A survey of pediatric neurosurgeons. J Neurosurg Pediatr. 2011
  7. [CrossRef] 7. Roujeau T, Machado G, Garnett MR, et al. Stereotactic biopsy of diffuse pontine lesions in children. J Neurosurg. 2007
  8. 107(Suppl. 1):1- 4. [CrossRef] 8. Cage TA, Samagh SP, Mueller S, et al. Feasibility, safety, and indications for surgical biopsy of intrinsic brainstem tumors in children. Childs Nerv Syst. 2013
  9. [CrossRef] 9. Kebudi R, Cakir FB. Management of diffuse pontine gliomas in children: Recent developments. Pediatr Drugs. 2013
  10. [Cross- Ref] 10. Zaghloul MS, Eldebawy E, Ahmed S, et al. Hypofractionated conformal radiotherapy for pediatric diffuse intrinsic pontine glioma (DIPG): A randomized controlled trial. Radiother Oncol. 2014
  11. [CrossRef] 11. Saratsis A, Kambhampati M, Snyder K, et al. Comparative multidimensional molecular analyses of pediatric diffuse intrinsic pontine glioma reveals distinct molecular subtypes. Acta Neuropathol. 2014
  12. [CrossRef] 12. Rineer J, Schreiber D, Choi K, Rotman M. Characterization and outcomes of infratentorial malignant glioma: A population-based study using the surveillance epidemiology and end-results database. Radiother Oncol. 2010
  13. [CrossRef] 13. Wu G, Diaz AK, Paugh BS, et al. The genomic landscape of diffuse intrinsic pontine glioma and pediatric